Novartis to buy Excellergy for up to $2B to boost allergy portfolio
Source: SeekingAlpha
2026-03-27 03:43:17 ET
More on Novartis
- Novartis Promises Growth Despite 'Historic' Patent Cliffs - I Broadly Agree
- Novartis: Synnovation Deal And 8% Full-Year 2025 Sales Growth
- Novartis (NVS) Shareholder/Analyst Call Prepared Remarks Transcript
- Novartis to buy experimental breast cancer drug for up to $3B
Read the full article on Seeking Alpha
For further details see:
Novartis to buy Excellergy for up to $2B to boost allergy portfolio
Novartis AG
NASDAQ: NVS
NVS Trading
-0.26% G/L:
$150.47 Last:
852,043 Volume:
$151.84 Open:
NVS Latest News
February 24, 2026 04:52:00 pm
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
NVS Stock Data
$303,205,301,793
1,889,070,162
N/A
868
N/A
Pharmaceuticals
Healthcare
CH
Basel
